Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genentech (NYSE:DNA) formerly known as (NYSE:GNE) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (247)	3/11/2009 12:54:53 PM
From: kenhott	Respond to of 250

Genentech, Roche Deal Hits Snag By MATTHEW KARNITSCHNIG and DANA CIMILLUCA, WSJ Deal talks between Genentech Inc. and Roche Holding AG have hit a snag over dueling interpretations of arcane U.S. Securities and Exchange Commission rules, but the problem is unlikely to derail the transaction, according to people familiar with the matter. The two drug makers have agreed in principle on the terms of a deal that would value the 44% of Genentech that Roche doesn't already own at $46.7 billion, or $95 per share. But efforts to reach an agreement have been hampered by Roche's outstanding tender offer for Genentech shares, which expires on March 20. The two camps were scrambling Wednesday to resolve the problem. The issue holding up the deal is how long Roche needs to leave the tender open after reaching an agreement with Genentech's board. A longer period would create a problem for Roche. It wants to sew up the deal before April, when a drug trial on Genentech's new cancer treatment, Avastin, is to be published, say people familiar with the matter. Roche is concerned that Genentech's shareholders would hold out for more money if the results are better than expected. A Roche spokeswoman had no immediate comment, and a Genentech spokesperson declined to comment. Speculation spread through the market on Tuesday that there was a dispute between the two camps over amending Genentech's so-called "affiliation agreement" with Roche, which sets forth the conditions Roche must meet to complete a merger, but people close to the transaction downplayed those concerns. In order to reach a deal Genentech must agree to amend the agreement by dropping certain conditions. Those issues have largely been resolved, says a person familiar with the matter, and aren't a major issue in the current negotiations. Roche, based in Switzerland, needs to receive consent from holders representing 90% of Genentech's outstanding shares to secure full ownership of the company.